JPH09500526A - テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御 - Google Patents
テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御Info
- Publication number
- JPH09500526A JPH09500526A JP7502191A JP50219195A JPH09500526A JP H09500526 A JPH09500526 A JP H09500526A JP 7502191 A JP7502191 A JP 7502191A JP 50219195 A JP50219195 A JP 50219195A JP H09500526 A JPH09500526 A JP H09500526A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- tta
- dna molecule
- interest
- tetracycline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 168
- 239000004098 Tetracycline Substances 0.000 title claims abstract description 145
- 235000019364 tetracycline Nutrition 0.000 title claims abstract description 145
- 229960002180 tetracycline Drugs 0.000 title claims abstract description 143
- 229930101283 tetracycline Natural products 0.000 title claims abstract description 143
- 150000003522 tetracyclines Chemical class 0.000 title claims abstract description 143
- 230000033228 biological regulation Effects 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 351
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 289
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 283
- 210000004027 cell Anatomy 0.000 claims abstract description 270
- 108020004414 DNA Proteins 0.000 claims abstract description 144
- 241001465754 Metazoa Species 0.000 claims abstract description 140
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 86
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 86
- 239000002157 polynucleotide Substances 0.000 claims abstract description 86
- 230000009261 transgenic effect Effects 0.000 claims abstract description 71
- 108700019146 Transgenes Proteins 0.000 claims abstract description 65
- 102000053602 DNA Human genes 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 60
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 230000006801 homologous recombination Effects 0.000 claims abstract description 48
- 238000002744 homologous recombination Methods 0.000 claims abstract description 48
- 229920001184 polypeptide Polymers 0.000 claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 46
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims abstract description 20
- 210000000349 chromosome Anatomy 0.000 claims abstract description 16
- 230000035897 transcription Effects 0.000 claims description 84
- 238000013518 transcription Methods 0.000 claims description 84
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 230000001105 regulatory effect Effects 0.000 claims description 54
- 108091026890 Coding region Proteins 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 17
- 230000003993 interaction Effects 0.000 claims description 17
- 241000700584 Simplexvirus Species 0.000 claims description 16
- 210000000604 fetal stem cell Anatomy 0.000 claims description 15
- 210000002459 blastocyst Anatomy 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 210000000287 oocyte Anatomy 0.000 claims description 12
- 241000238631 Hexapoda Species 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 241000701022 Cytomegalovirus Species 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 239000013611 chromosomal DNA Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- -1 Trophin Proteins 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 108020004440 Thymidine kinase Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 101710094648 Coat protein Proteins 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 229930193140 Neomycin Natural products 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- 102000006467 TATA-Box Binding Protein Human genes 0.000 claims description 4
- 108010044281 TATA-Box Binding Protein Proteins 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108700002232 Immediate-Early Genes Proteins 0.000 claims description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims description 3
- 101150003725 TK gene Proteins 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 239000012212 insulator Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 2
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102100023915 Insulin Human genes 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims description 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 2
- 229960004222 factor ix Drugs 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 108700001097 Insect Genes Proteins 0.000 claims 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 230000000754 repressing effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 32
- 102000037865 fusion proteins Human genes 0.000 abstract description 23
- 108020001507 fusion proteins Proteins 0.000 abstract description 23
- 230000008685 targeting Effects 0.000 abstract description 15
- 230000002779 inactivation Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 49
- 108060001084 Luciferase Proteins 0.000 description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 description 45
- 239000005089 Luciferase Substances 0.000 description 44
- 101150061166 tetR gene Proteins 0.000 description 31
- 230000004913 activation Effects 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 239000002609 medium Substances 0.000 description 21
- 101150024821 tetO gene Proteins 0.000 description 21
- 239000012634 fragment Substances 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 239000000306 component Substances 0.000 description 15
- 230000002068 genetic effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 230000004927 fusion Effects 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 10
- 108020004635 Complementary DNA Proteins 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 9
- 102000016736 Cyclin Human genes 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 238000010804 cDNA synthesis Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 108091006106 transcriptional activators Proteins 0.000 description 9
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 102100040296 TATA-box-binding protein Human genes 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 230000013011 mating Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000008488 polyadenylation Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 101100174784 Bacillus subtilis (strain 168) ganR gene Proteins 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 101150043267 lacR gene Proteins 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000005026 transcription initiation Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 108700009124 Transcription Initiation Site Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 3
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000037919 acquired disease Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000014493 regulation of gene expression Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 101100166166 Drosophila melanogaster cas gene Proteins 0.000 description 2
- 108010008488 Glycylglycine Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 229940043257 glycylglycine Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001167 myeloblast Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWFJMIVZYSDULZ-DVJPNYBFSA-N (4r,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-DVJPNYBFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283715 Damaliscus lunatus Species 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102000006580 General Transcription Factors Human genes 0.000 description 1
- 108010008945 General Transcription Factors Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
- 101150082943 NAT1 gene Proteins 0.000 description 1
- 241000511989 Neomys Species 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000622060 Photinus pyralis Luciferin 4-monooxygenase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101150020201 RB gene Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 241000984929 Tibeta Species 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241001440806 Tyta Species 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 108700025184 hepatitis B virus X Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 238000002961 luciferase induction Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical class C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.テトラサイクリン制御可能なトランスアクチベーター(tTA)をコード化 するポリヌクレオチド配列を、第二標的DNA分子中の所定の位置に組み込むた めの分離されたDNA分子であって、tTAは、原核Tetリプレッサーを、真 核細胞において転写を間接に或は直接に活性化するポリペプチドに作動可能に結 合させて含み、DNA分子は、tTAをコード化するポリヌクレオチド配列の5 ’及び3’末端に側面に、所定の位置においてDNA分子と第二標的DNA分子 との間で相同的に組み換えるための十分な長さの更なるポリヌクレオチド配列を 位置させてなる分離されたDNA分子。 2.tTAをコード化するポリヌクレオチド配列を側面に位置させる更なるポリ ヌクレオチド配列が、DNA分子が装入される関心ある遺伝子、或はその調節領 域のものである請求項1のDNA分子。 3.DNA分子を関心ある遺伝子、或はその調節領域中に組み込む際に、tTA の発現を関心ある遺伝子の調節要素によって調節する請求項2のDNA分子。 4.tTAのTetリプレッサーが、Tn10由来のTetリプレッサーである 請求項1のDNA分子。 5.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチド が、単純ヘルペスウイルスビリオン蛋白質16からのものである請求項1のDN A分 子。 6.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチド を、酸性、プロリンリッチ、セリン/トレオニンリッチ及びグルタミンリッチ転 写活性化ポリペプチドからなる群より選ぶ請求項1のDNA分子。 7.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチド が、ロイシンジッパードメイン、ヘリックス−ループ−ヘリックスドメイン及び 亜鉛フィンガードメインからなる群より選ぶ相互作用ドメインである請求項1の DNA分子。 8.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチド が、TATA結合蛋白質からの相互作用ドメインである請求項1のDNA分子。 9.更に、選択可能な標識をコード化するポリヌクレオチド配列を含む請求項1 のDNA分子。 10.選択可能な標識をコード化するポリヌクレオチド配列が、tk遺伝子或は ネオマイシン耐性遺伝子である請求項9のDNA分子。 11.a)関心ある遺伝子の5’隣接調節領域を、下記に作動可能に結合させて なる第一ポリヌクレオチド配列: b)原核Tetリプレッサーを、真核細胞において転写を間接に或は直接に活 性化するポリペプチドに作動可能に結合させてなるtTAをコード化する第二ポ リヌク レオチド配列;及び c)tTA反応性プロモーターを、下記に作動可能に結合させてなる第三ポリ ヌクレオチド配列: d)関心ある遺伝子のコード化領域の少なくとも一部を含む第四ポリヌクレオ チド配列 を含み、第一及び第四ポリヌクレオチド配列は、第二標的DNA分子においてD NA分子と関心ある遺伝子との間で相同的に組み換えるための十分な長さにし、 それでtTAの発現が関心ある遺伝子の5’調節要素によって調節されかつ関心 ある遺伝子の発現がtTA反応性プロモーターによって調節されるようにする、 テトラサイクリン制御可能なトランスアクチベーター(tTA)をコード化する ポリヌクレオチド配列及びtTA反応性プロモーターを、第二標的DNA分子中 の所定の関心ある遺伝子内に組み込むための分離されたDNA分子。 12.更に、選択可能な標識をコード化する第五ポリヌクレオチド配列を調節配 列に作動可能に結合させてなり、第五ポリヌクレオチド配列は、第二ポリヌクレ オチド配列と第三ポリヌクレオチド配列との間に配置される請求項11のDNA 分子。 13.選択可能な標識をコード化する第五ポリヌクレオチド配列が、tk遺伝子 或はネオマイシン耐性遺伝子である請求項12のDNA分子。 14.更に、転写ターミネーターシグナル、転写インシュレーター或はマトリッ クス結合領域を含む第五ポリヌ クレオチド配列を含み、第五ポリヌクレオチド配列は、第二ポリヌクレオチド配 列と第三ポリヌクレオチド配列との間に配置される請求項11のDNA分子。 15.更に、転写ターミネーターシグナル、転写インシュレーター或はマトリッ クス結合領域を含む第六ポリヌクレオチド配列を含み、第六ポリヌクレオチド配 列は、第五ポリヌクレオチド配列と第三ポリヌクレオチド配列との間に配置され る請求項12のDNA分子。 16.tTAのTetリプレッサーが、Tn10由来のTetリプレッサーであ る請求項11のDNA分子。 17.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドが、単純ヘルペスウイルスビリオン蛋白質16からのものである請求項11の DNA分子。 18.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドを、酸性、プロリンリッチ、セリン/トレオニンリッチ及びグルタミンリッチ 転写活性化ポリペプチドからなる群より選ぶ請求項11のDNA分子。 19.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドが、ロイシンジッパードメイン、ヘリックス−ループ−ヘリックスドメイン及 び亜鉛フィンガードメインからなる群より選ぶ相互作用ドメインである請求項1 1のDNA分子。 20.真核細胞において転写を間接に或は直接に活性化 するtTAのポリペプチドが、TATA結合蛋白質からの相互作用ドメインであ る請求項11のDNA分子。 21.第三ヌクレオチド配列のtTA反応性プロモーターが、最小プロモーター を少なくとも1つのtetオペレーター配列に作動可能に結合させてなる請求項 11のDNA分子。 22.最小プロモーターが、サイトメガロウイルス即時型初期遺伝子プロモータ ー或は単純ヘルペスウイルスチミジンキナーゼ遺伝子プロモーターに由来する請 求項21のDNA分子。 23.関心ある遺伝子が、ヒト遺伝子である請求項11のDNA分子。 24.ヒト遺伝子が、アデノシンデアミナーゼ、因子VIII、因子IX、ジス トロフィン、β−グロビン、LDL、レセプター、CFTR、インシュリン、エ リトロポエチン、抗血管形成因子、成長ホルモン、グルコセレブロシダーゼ、β −グルコウロニダーゼ、α1−アンチトリプシン、フェニルアラニンヒドロキシ ラーゼ、チロシンヒドロキシラーゼ、オルニチントランスカルバミラーゼ、アル ギノスクシネートシンセターゼ、UDP−グルクロニシルトランスフェラーゼ、 apoA1、MDR1、MRP、TNF、可溶性TNFレセプター、インターロ イキン、インターフェロン、サイトカイネ、成長因子及び腫瘍サプレッサー遺伝 子からなる群より選 ぶ遺伝子生成物をコード化する請求項23のDNA分子。 25.DNA分子が、宿主細胞における第二標的DNA分子中の所定の位置に組 み込まれる請求項1のDNA分子を含む真核宿主細胞。 26.更に、関心ある遺伝子をtTA反応性転写プロモーターに作動可能に結合 させてなる請求項25の宿主細胞。 27.tTA反応性転写プロモーターが、最小プロモーターを少なくとも1つの tetオペレーター配列に作動可能に結合させてなる請求項26の宿主細胞。 28.最小プロモーターが、サイトメガロウイルス即時型初期遺伝子プロモータ ー或は単純ヘルペスウイルスチミジンキナーゼ遺伝子プロモーターに由来する請 求項27のDNA分子。 29.哺乳動物細胞である請求項25の宿主細胞。 30.ヒト細胞である請求項29の宿主細胞。 31.胎児幹細胞である請求項29の宿主細胞。 32.酵母細胞或はカビ細胞である請求項25の宿主細胞。 33.細胞が昆虫細胞であり、第二標的DNA分子が昆虫遺伝子或はバキュロウ イルス遺伝子である請求項25の宿主細胞。 34.細胞にテトラサイクリン或はテトラサイクリン類似体を接触させることを 含む、請求項26の宿主細胞に おいてtTA反応性プロモーターに作動可能に結合された関心ある遺伝子の転写 を抑制する方法。 35.核酸が、宿主細胞における第二標的DNA分子中の所定の関心ある遺伝子 に組み込まれる請求項11の核酸を含む宿主細胞。 36.哺乳動物細胞である請求項35の宿主細胞。 37.ヒト細胞である請求項36の宿主細胞。 38.胎児幹細胞である請求項36の宿主細胞。 39.酵母細胞或はカビ細胞である請求項35の宿主細胞。 40.細胞が昆虫細胞であり、関心ある遺伝子が昆虫遺伝子或はバキュロウイル ス遺伝子である請求項35の宿主細胞。 41.細胞にテトラサイクリン或はテトラサイクリン類似体を接触させることを 含む、請求項35の宿主細胞において関心ある真核遺伝子の転写を抑制する方法 。 42.テトラサイクリン制御可能なトランスアクチベーター(tTA)をコード 化するポリヌクレオチド配列を含むトランスジーンを含み、tTAは、原核Te tリプレッサーを、真核細胞において転写を間接に或は直接に活性化するポリペ プチドに作動可能に結合させて含む非ヒトトランスジェニック動物。 43.tTAのTetリプレッサーが、Tn10由来のTetリプレッサーであ る請求項42の動物。 44.真核細胞において転写を間接に或は直接に活性化 するtTAのポリペプチドが、単純ヘルペスウイルスビリオン蛋白質16からの ものである請求項42の動物。 45.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドを、酸性、プロリンリッチ、セリン/トレオニンリッチ及びグルタミンリッチ 転写活性化ポリペプチドからなる群より選ぶ請求項42の動物。 46.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドが、ロイシンジッパードメイン、ヘリックス−ループ−ヘリックスドメイン及 び亜鉛フィンガードメインからなる群より選ぶ相互作用ドメインである請求項4 2の動物。 47.真核細胞において転写を間接に或は直接に活性化するtTAのポリペプチ ドが、TATA結合蛋白質からの相互作用ドメインである請求項42の動物。 48.更に、関心ある遺伝子をtTA反応性転写プロモーターに作動可能に結合 させてなる第二トランスジーンを有する請求項42の動物。 49.マウスである請求項42の動物。 50.牛、山羊、羊及び豚からなる群より選ぶ請求項42の動物。 51.テトラサイクリン或はテトラサイクリン類似体を動物に投与することを含 む、請求項48のトランスジェニック動物において第二トランスジーンの転写を 抑制す る方法。 52.テトラサイクリン制御可能なトランスアクチベーター(tTA)をコード 化するポリヌクレオチド配列を含むトランスジーンを有し、tTAは、原核Te tリプレッサーを、真核細胞において転写を間接に或は直接に活性化するポリペ プチドに作動可能に結合させてなり、トランスジーンは、動物の細胞内の染色体 内の所定の位置に相同的組み換えによって組み込まれる非ヒトトランスジェニッ ク動物。 53.更に、tTA反応性転写プロモーターに作動可能に結合された関心ある遺 伝子を含む第二トランスジーンを有する請求項52の動物。 54.テトラサイクリン或はテトラサイクリン類似体を動物に投与することを含 む、請求項53の動物において第二トランスジーンの転写を抑制する方法。 55.テトラサイクリン制御可能なトランスアクチベーター(tTA)をコード 化するポリヌクレオチド配列を含むトランス遺伝子及びtTA反応性プロモータ ーを有し、tTAの発現が関心ある遺伝子の5’調節要素によって調節されかつ 関心ある遺伝子の発現がtTA反応性プロモーターによって調節されるように、 トランスジーンは、動物の細胞内の関心ある遺伝子内の所定の位置に相同的組み 換えによって組み込まれるトランスジェニック動物。 56.テトラサイクリン或はテトラサイクリン類似体を 動物に投与することを含む、請求項55の動物において関心ある遺伝子の転写を 抑制する方法。 57.請求項26の細胞においてtTA反応性転写プロモーターに作動可能に結 合された関心ある遺伝子によってコード化された遺伝子生成物を産生しかつ分離 する方法であって、 a)細胞を培地中でテトラサイクリン或はテトラサイクリン類似体の存在にお いて増殖させ; b)テトラサイクリン或はテトラサイクリン類似体の濃度を減少させて関心あ る遺伝子の転写を剌激し; c)更に、関心ある遺伝子によってコード化される遺伝子生成物が細胞によっ て所望の量で産生されるまで細胞を培養し:及び d)収穫した細胞から或は培地から遺伝子生成物を分離する ことを含む方法。 58.細胞が哺乳動物細胞である請求項57の方法。 59.細胞が酵母或はカビ細胞である請求項57の方法。 60.請求項42の非ヒトトランスジェニック動物を産生する方法であって、 a)tTAをコード化するDNA分子を受精された卵母細胞に導入し; b)受精された卵母細胞を偽妊娠養育母親に移植し; 及び c)受精された卵母細胞を非ヒトトランスジェニック動物に成長させてそれに より非ヒトトランスジェニック動物を産生する ことを含む方法。 61.細胞内の第二標的DNA分子中の所定の位置に組み込んだテトラサイクリ ン制御可能なトランスアクチベーター(tTA)をコード化するDNA分子を有 する宿主細胞を産生する方法であって、 a)請求項1のDNA分子を細胞の集団中に、tTAをコード化するDNAと 第二標的DNA分子との間で相同的に組み換えるのに適した条件下で導入し;及 び b)tTAをコード化するDNAが、第二標的DNA分子内の所定の位置にお いて合体している細胞を選ぶことを含む方法。 62.動物の細胞の染色体DNA内の所定の位置に組み込んだテトラサイクリン 制御可能なトランスアクチベーター(tTA)をコード化するトランスジーンを 有する非ヒトトランスジェニック動物を産生する方法であって、 a)請求項1のDNA分子を胎児幹細胞の集団中に、tTAをコード化するD NAと細胞内の染色体DNAとの間で相同的に組み換えるのに適した条件下で導 入し; b)tTAをコード化するDNAが、細胞の染色体DNA内の所定の位置にお いて合体している胎児幹細胞を選び; c)胎児幹細胞を胚盤胞に移植し;及び d)胚盤胞を偽妊娠養育母親に移植し;及び e)胚盤胞を非ヒトトランスジェニック動物に成長させてそれにより非ヒトト ランスジェニック動物を産生する ことを含む方法。 63.動物の細胞の関心ある遺伝子内の所定の位置に組み込んだテトラサイクリ ン制御可能なトランスアクチベーター(tTA)をコード化するトランス遺伝子 及びtTA反応性プロモーターを有する非ヒトトランスジェニック動物を産生す る方法であって、 a)請求項11のDNA分子を胎児幹細胞の集団中に、tTAをコード化する DNAと細胞内の関心ある遺伝子との間で相同的に組み換えるのに適した条件下 で導入し; b)tTAをコード化するDNAが、細胞中の関心ある遺伝子内の所定の位置 において合体している胎児幹細胞を選び; c)胎児幹細胞を胚盤胞に移植し;及び d)胚盤胞を偽妊娠養育母親に移植し;及び e)胚盤胞を非ヒトトランスジェニック動物に成長させてそれにより非ヒトト ランスジェニック動物を産生する ことを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7632793A | 1993-06-14 | 1993-06-14 | |
US08/076,327 | 1993-06-14 | ||
PCT/US1994/006734 WO1994029442A2 (en) | 1993-06-14 | 1994-06-14 | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09500526A true JPH09500526A (ja) | 1997-01-21 |
Family
ID=22131308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7502191A Pending JPH09500526A (ja) | 1993-06-14 | 1994-06-14 | テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御 |
Country Status (8)
Country | Link |
---|---|
US (3) | US5650298A (ja) |
EP (1) | EP0705334A1 (ja) |
JP (1) | JPH09500526A (ja) |
AU (1) | AU684524B2 (ja) |
CA (1) | CA2165162C (ja) |
DE (1) | DE705334T1 (ja) |
ES (1) | ES2140359T1 (ja) |
WO (1) | WO1994029442A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003515314A (ja) * | 1999-06-07 | 2003-05-07 | ウォルフガング ハイレン | 新規の、tetリプレッサーに基づく転写調節タンパク質 |
JP2005527227A (ja) * | 2002-05-29 | 2005-09-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 誘導性の真核生物発現システム |
JP2009538122A (ja) * | 2006-04-18 | 2009-11-05 | ジェノスクリーン | 脳の損傷を診断するためのマーカーとしてのオルニチントランスカルバミラーゼ(otc)の使用 |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888981A (en) | 1993-06-14 | 1999-03-30 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5789156A (en) * | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5866755A (en) * | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
US5912411A (en) * | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
US5859310A (en) | 1993-06-14 | 1999-01-12 | Basf Aktiengesellschaft | Mice transgenic for a tetracycline-controlled transcriptional activator |
DE705334T1 (de) | 1993-06-14 | 1999-12-30 | Basf Ag | Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren |
US5654168A (en) * | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
US6004941A (en) * | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5589362A (en) * | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
AU1662595A (en) * | 1994-01-28 | 1995-08-15 | Herbert Altmann | Method of determining the activity of a regulatory factor, and use of the method |
AU746850B2 (en) * | 1994-07-01 | 2002-05-02 | Tet Systems Holding Gmbh & Co. Kg | Tetracycline-regulated transcriptional modulaters |
US5935849A (en) * | 1994-07-20 | 1999-08-10 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
US5776747A (en) * | 1994-07-20 | 1998-07-07 | Cytotherapeutics, Inc. | Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer |
GB9425600D0 (en) * | 1994-12-19 | 1995-02-15 | Medical Res Council | Targeting complexes and use thereof |
FR2732348B1 (fr) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Systeme d'expression conditionnel |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
US6495364B2 (en) | 1995-05-23 | 2002-12-17 | Neurotech, S.A. | Mx-1 conditionally immortalized cells |
ATE429499T1 (de) | 1995-06-23 | 2009-05-15 | Danisco | Neuartige methode zur isolierung von mutanten und zur klonierung der complementierenden gene |
GB9616685D0 (en) * | 1995-10-02 | 1996-09-25 | Cancer Res Campaign Tech | Antitumour vector constructs and methods |
DE19542051C2 (de) | 1995-11-10 | 2000-03-23 | Asta Medica Ag | Gentechnisch veränderte tumorigene Zellinien und Verwendung derselben für die Testung von Antitumor-Wirkstoffen |
TR199801113T2 (xx) * | 1995-12-22 | 1998-10-21 | E.I. Du Pont De Nemours And Company | Rekombinan bakulovir�slerin �retimi. |
GB9526509D0 (en) * | 1995-12-23 | 1996-02-28 | Univ Dundee | Gene control |
US5891718A (en) * | 1996-03-27 | 1999-04-06 | Vical Incorporated | Tetracycline inducible/repressible systems |
US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5905042A (en) * | 1996-04-01 | 1999-05-18 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Cultured inner cell mass cell lines derived from bovine or porcine embryos |
WO1998003060A1 (fr) * | 1996-07-24 | 1998-01-29 | The Tokyo Metropolitan Institute Of Medical Science | Modeles animaux de l'hepatite c |
US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
DE19635568C1 (de) * | 1996-09-02 | 1998-03-26 | Gsf Forschungszentrum Umwelt | Vektorsysteme zur konditionalen Genexpression |
JPH1080274A (ja) * | 1996-09-06 | 1998-03-31 | Hirofumi Hamada | 核移行シグナルを結合したテトラサイクリン・トランスアクチベーター |
DE19639103A1 (de) * | 1996-09-24 | 1998-03-26 | Hoechst Ag | Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
CA2276529A1 (en) | 1996-12-31 | 1998-07-09 | George A. Gaitanaris | Vectors and methods for the mutagenesis of mammalian genes |
US6235969B1 (en) | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
US6215041B1 (en) | 1997-01-10 | 2001-04-10 | University Of Mmassachusetts | Cloning using donor nuclei from a non-quiesecent somatic cells |
JP3240370B2 (ja) * | 1997-01-17 | 2001-12-17 | 農林水産省畜産試験場長 | 培養細胞または受精卵に外来遺伝子を導入する方法 |
DE19707493C1 (de) * | 1997-02-25 | 1998-02-26 | Univ Ludwigs Albert | Nucleinsäurekonstrukte zur lang andauernden Expression von Transgenen |
FR2761576B1 (fr) * | 1997-04-04 | 2002-08-30 | Inst Nat Sante Rech Med | Animal transgenique non humain dans lequel l'expression du gene codant pour l'insuline est supprimee |
US6087166A (en) | 1997-07-03 | 2000-07-11 | Basf Aktiengesellschaft | Transcriptional activators with graded transactivation potential |
AU9386198A (en) | 1997-09-10 | 1999-03-29 | President And Fellows Of Harvard College | Inducible methods for repressing gene function |
DK1015576T3 (da) * | 1997-09-16 | 2005-08-29 | Egea Biosciences Llc | Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
JP2001520170A (ja) | 1997-10-16 | 2001-10-30 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Nf−at3機能に関連した心肥大動物モデルと治療法 |
US6136536A (en) * | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
US6613958B1 (en) | 1997-12-19 | 2003-09-02 | Wyeth | Transgenic mouse model for degeneration of type II collagen in joints |
AU2312699A (en) * | 1998-01-16 | 1999-08-02 | Pharmacia & Upjohn Company | An autoregulatory system for validating microbial genes as possible antimicrobial targets using tetracycline-controllable element |
US6878516B1 (en) | 1998-01-16 | 2005-04-12 | Pharmacia & Upjohn Company | Autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element |
US6194633B1 (en) | 1998-01-26 | 2001-02-27 | University Of Iowa Research Foundation | Non-human animal having a functionally disrupted SLP-76 gene |
US7037663B2 (en) * | 1998-02-19 | 2006-05-02 | Eastern Virginia Medical School | Human zona pellucida protein 3 and uses thereof |
DE69922489T2 (de) * | 1998-02-19 | 2005-12-15 | Eastern Virginia Medical School | Rekombinantes aktives humanes Zona Pellucida |
DE19808453C2 (de) * | 1998-02-27 | 2000-12-14 | Gsf Forschungszentrum Umwelt | Expressionsvektor zur konditionalen Regulation der Expression der großen Untereinheit der RNA-Polymerase II |
GB2337519A (en) * | 1998-05-19 | 1999-11-24 | Univ Bristol | Transgenic mammal comprising specific means for regulation of transgene expression |
DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
EP1123401A1 (en) * | 1998-10-22 | 2001-08-16 | The General Hospital Corporation | BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
DE69929718T2 (de) * | 1998-11-09 | 2006-11-09 | Aventis Pharma S.A. | Neues regulationssystem zur kontrolle der expression eines transgens |
FR2786198B1 (fr) * | 1998-11-09 | 2003-02-14 | Aventis Pharma Sa | Nouveau systeme de regulation de l'expression d'un transgene |
US7189506B1 (en) | 1999-03-03 | 2007-03-13 | Genelabs Technologies, Inc. | DNA binding compound-mediated molecular switch system |
CA2367037A1 (en) * | 1999-03-03 | 2000-09-08 | Genelabs Technologies, Inc. | Dna binding compound-mediated molecular switch system |
US6440741B2 (en) * | 1999-03-15 | 2002-08-27 | The Trustees Of Columbia University In The City Of New York | Expression vector for consistent cellular expression of the tet on repressor in multiple cell types |
AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
US6890726B1 (en) | 1999-04-06 | 2005-05-10 | Oklahoma Medical Research Foundation | Method for selecting recombinase variants with altered specificity |
WO2000062604A1 (en) * | 1999-04-16 | 2000-10-26 | The Ohio State University Research Foundation | Genetic system for controlling background expression of transgene products |
US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
AU778150B2 (en) * | 1999-05-28 | 2004-11-18 | Gendaq Limited | Molecular switches |
AU4940700A (en) | 1999-05-28 | 2000-12-18 | Sangamo Biosciences, Inc. | Gene switches |
EP1203098A2 (en) * | 1999-07-30 | 2002-05-08 | University College London | Inducible screen for drug discovery |
JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
CA2382939C (en) * | 1999-08-24 | 2014-11-04 | Una Chen-Bettecken | Method for growing stem cells |
US6780639B1 (en) | 1999-08-24 | 2004-08-24 | Universite Libre De Bruxelles | Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization |
US7408047B1 (en) * | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6900043B1 (en) * | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
ATE412670T1 (de) | 1999-09-29 | 2008-11-15 | Gen Hospital Corp | Parathyroid hormon (pth) polypeptidderivate |
US7022815B1 (en) | 1999-09-29 | 2006-04-04 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (PTH) |
US6908612B2 (en) | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
PT1254169E (pt) | 1999-12-30 | 2007-08-21 | Harvard College | ''métodos relativos à modulação da actividade do subconjunto de células th2 por modulação da actividade de xbp-1'' |
US7132277B1 (en) | 2000-01-31 | 2006-11-07 | Merck & Co., Inc. | Helper dependent vector system for gene therapy |
US20050239061A1 (en) * | 2000-03-01 | 2005-10-27 | Marshall William S | Identification and use of effectors and allosteric molecules for the alteration of gene expression |
ATE525091T1 (de) | 2000-03-13 | 2011-10-15 | Engene Inc | Zusammensetzungen und verfahren zur regulierten proteinexpression im darm |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
US6825038B2 (en) | 2000-05-12 | 2004-11-30 | The Johns Hopkins University | Method for generating hypermutable organisms |
EP2077279B1 (en) | 2000-06-28 | 2012-09-05 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
WO2002008286A2 (en) * | 2000-07-21 | 2002-01-31 | Syngenta Participations Ag | Zinc finger domain recognition code and uses thereof |
US20030082561A1 (en) * | 2000-07-21 | 2003-05-01 | Takashi Sera | Zinc finger domain recognition code and uses thereof |
AU2001293798B2 (en) * | 2000-09-09 | 2006-12-21 | Basf Plant Science Gmbh | Modified tet-inducible system for regulation of gene expression in plants |
WO2002022834A2 (en) * | 2000-09-15 | 2002-03-21 | Deltagen, Inc. | Methods of producing cells and animals comprising targeted gene modifications |
AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
DE60227361D1 (de) * | 2001-01-19 | 2008-08-14 | Centocor Inc | Computer vermitteltes assembly von polynucleotiden kodierend für ein zielgerichtetes polypeptide |
EP1383912A4 (en) | 2001-04-02 | 2007-11-28 | Wyeth Corp | PD-1, A RECEPTOR FOR B7-4, AND USES THEREOF |
CA2446110C (en) * | 2001-05-01 | 2013-06-25 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
US20030154499A1 (en) * | 2001-06-08 | 2003-08-14 | Monika Wasel-Nielen | Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor |
WO2003009804A2 (en) * | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
EP1421104A4 (en) * | 2001-08-02 | 2005-08-24 | Trinity Biomedical Technology | HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE |
WO2003027260A2 (en) * | 2001-09-27 | 2003-04-03 | Functional Genetics, Inc. | Methods and compositions for generating homozygous mutations |
US20030221203A1 (en) * | 2001-10-03 | 2003-11-27 | Agha-Mohammadi Siamak | High efficiency regulatable gene expression system |
WO2003037260A2 (en) * | 2001-10-30 | 2003-05-08 | Biogen, Inc. | Methods and compositions for treating parkinson's disease |
AU2003217693A1 (en) * | 2002-02-22 | 2003-09-09 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
US7579515B2 (en) * | 2002-12-24 | 2009-08-25 | North Carolina State University | Increasing gamete production with a gene switch |
EP2201960A1 (en) * | 2003-03-19 | 2010-06-30 | The General Hospital Corporation | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
US7459152B2 (en) * | 2003-04-23 | 2008-12-02 | Rush University Medical Center | Erythropoietin administration to improve graft survival |
US8903512B2 (en) * | 2003-05-15 | 2014-12-02 | Medtronic, Inc. | Medical system including a novel bipolar pacing pair |
WO2005014785A2 (en) * | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
US7910544B2 (en) | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
WO2005010039A1 (en) * | 2003-07-31 | 2005-02-03 | Pfizer Products Inc. | Bsep polypeptide variants and uses thereof |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
CA2543257C (en) | 2003-10-24 | 2013-12-31 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
US20050287668A1 (en) * | 2003-11-04 | 2005-12-29 | Cell Therapeutics, Inc. (Cti) | RNA interference compositions and screening methods for the identification of novel genes and biological pathways |
WO2005046450A2 (en) | 2003-11-12 | 2005-05-26 | Children's Hospital Medical Center | Method for diagnosis and treatment of pulmonary disorders |
US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
US20060063187A1 (en) * | 2004-09-15 | 2006-03-23 | Hotamisligil Gokhan S | Modulation of XBP-1 activity for treatment of metabolic disorders |
US7736650B2 (en) | 2004-12-21 | 2010-06-15 | Centocor, Inc. | Anti-IL-12 antibody based vectors, host cells, and methods of production and uses |
WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
CA2604580A1 (en) | 2005-04-15 | 2006-10-26 | President And Fellows Of Harvard College | Methods for modulating bone formation and mineralization by modulating krc activity |
CA2623106C (en) | 2005-09-19 | 2013-12-24 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
AU2007231008A1 (en) * | 2006-03-23 | 2007-10-04 | The Regents Of The University Of Michigan | Compositions and methods for generating transgenic animals |
US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
EP2026776A2 (en) | 2006-05-15 | 2009-02-25 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
US20080300202A1 (en) * | 2006-05-18 | 2008-12-04 | The State of Oregon acting by and through the State Board of Higher Education on behalf of the | Subtractive transgenics |
JP2009545320A (ja) * | 2006-08-04 | 2009-12-24 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモン(pth)のポリペプチド誘導体 |
WO2008064056A2 (en) * | 2006-11-22 | 2008-05-29 | Pioneer Hi-Bred International, Inc. | Tetracycline repressor and uses thereof |
US8679845B2 (en) * | 2007-05-31 | 2014-03-25 | University Of Washington | B cells modified to reversibly induce accelerated mutagenesis of target genes |
JP2010531638A (ja) | 2007-06-12 | 2010-09-30 | ケース ウエスタン リザーブ ユニバーシティ | 標的化された細胞死 |
BRPI0814962B8 (pt) * | 2007-08-01 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica |
DK2262905T3 (en) * | 2008-03-04 | 2015-05-26 | Centre Nat Rech Scient | Cell, method and kit for carrying out a test for neutralizing antibodies |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
EP2352833B1 (en) | 2008-10-01 | 2013-03-06 | TET Systems GmbH & Co. KG | Tetracycline inducible transcription control sequence |
WO2010042747A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010062518A1 (en) | 2008-10-28 | 2010-06-03 | Pioneer Hi-Bred International, Inc. | Sulfonylurea-responsive repressor proteins |
EP2727996A1 (en) | 2008-11-06 | 2014-05-07 | The Johns-Hopkins University | Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
TWI560197B (en) * | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
ES2804764T3 (es) | 2009-06-01 | 2021-02-09 | Halo Bio Rnai Therapeutics Inc | Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos |
MX2011013903A (es) * | 2009-06-17 | 2012-05-08 | Amgen Inc | Polipeptidos quimericos y usos de los mismos. |
JP2013512672A (ja) * | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトFGFR1c、ヒトβ−クロト−、ならびにヒトFGFR1cおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
US9745589B2 (en) | 2010-01-14 | 2017-08-29 | Cornell University | Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination |
BR112012021411A2 (pt) | 2010-02-25 | 2017-04-18 | Dana Farber Cancer Inst Inc | mutações braf que conferem resistência a inibidores braf. |
AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
RU2604809C2 (ru) | 2010-05-13 | 2016-12-10 | Дзе Дженерал Хоспитал Корпорейшн | Аналоги паратиреоидного гормона и их применение |
AU2011264833B2 (en) | 2010-06-09 | 2014-07-03 | Dana-Farber Cancer Institute, Inc. | A MEK 1 mutation conferring resistance to RAF and MEK inhibitors |
WO2012051301A1 (en) | 2010-10-12 | 2012-04-19 | President And Fellows Of Harvard College | Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism |
WO2012071549A2 (en) | 2010-11-24 | 2012-05-31 | Clontech Laboratories, Inc. | Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same |
US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
EP2710130B1 (en) | 2011-05-19 | 2022-06-29 | Fundación Pública Andaluza Progreso Y Salud | Highly inducible dual-promoter lentiviral tet-on system |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
WO2013033407A2 (en) | 2011-08-30 | 2013-03-07 | The Regents Of The University Of California | Identification of small molecules that enhance therapeutic exon skipping |
US9645151B2 (en) | 2012-08-17 | 2017-05-09 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
DK3049521T3 (en) | 2013-09-25 | 2019-04-23 | Univ Cornell | Compounds for inducing antitumor immunity and methods thereof |
US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
AU2016258984B2 (en) | 2015-05-05 | 2020-11-19 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
MX2018002090A (es) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos. |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
CN113699147B (zh) | 2020-05-22 | 2023-06-09 | 深圳市深研生物科技有限公司 | 基于四环素和Cumate的共调控序列 |
US11987795B2 (en) | 2020-11-24 | 2024-05-21 | The Broad Institute, Inc. | Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11 |
US11566262B2 (en) | 2021-03-24 | 2023-01-31 | Dna Twopointo Inc. | Tetracycline-inducible expression systems |
CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
EP4349979A1 (en) | 2021-05-27 | 2024-04-10 | Institute Of Zoology, Chinese Academy Of Sciences | Engineered cas12i nuclease, effector protein and use thereof |
WO2023178316A2 (en) | 2022-03-17 | 2023-09-21 | Yale University | Compositions and methods for expressing synthetic genetic elements across diverse microorganisms |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4850108A (ja) * | 1971-10-26 | 1973-07-14 | ||
JPS4928702A (ja) * | 1972-07-04 | 1974-03-14 | ||
JPS5069407A (ja) * | 1973-04-26 | 1975-06-10 | ||
JPS5848706A (ja) * | 1981-09-18 | 1983-03-22 | Toshiba Corp | ランキンサイクル装置 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
AU3102289A (en) * | 1988-03-11 | 1989-09-14 | Dana-Farber Cancer Institute, Inc. | Regulation of expression in mammalian cells |
US5221778A (en) * | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
GB8901676D0 (en) * | 1989-01-26 | 1989-03-15 | Ici Plc | Regulation of gene expression |
EP0484440A4 (en) | 1989-07-28 | 1993-01-07 | Us Health | Efficient directional genetic cloning system |
WO1991013979A1 (en) | 1990-03-05 | 1991-09-19 | President And Fellows Of Harvard College | Transgenic mouse overexpressing il-4 and method of use |
EP0455424A3 (en) * | 1990-05-02 | 1992-04-29 | Merck & Co. Inc. | Mammalian inducible promoter cascade system |
WO1991019796A1 (en) * | 1990-06-12 | 1991-12-26 | Baylor College Of Medicine | Method for homologous recombination in animal and plant cells |
AU8059891A (en) * | 1990-06-13 | 1992-01-07 | Trustees Of Princeton University, The | A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells |
EP0565638A1 (en) * | 1991-01-04 | 1993-10-20 | Baylor College Of Medicine | Tumor susceptible non-human animals |
DE4100594A1 (de) * | 1991-01-08 | 1992-07-09 | Inst Genbiologische Forschung | Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen |
ATE203269T1 (de) | 1991-03-15 | 2001-08-15 | Hsc Res Dev Ltd Partnership | Genherstellung zur produktion von transgenfisch |
AU664847B2 (en) * | 1991-05-15 | 1995-12-07 | Cell Genesys, Inc. | Genomic modifications with homologous DNA targeting |
WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0745121B1 (en) * | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
EP0665883A1 (en) * | 1992-08-26 | 1995-08-09 | Dnx Corporation | Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals |
PL310327A1 (en) * | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
DE705334T1 (de) | 1993-06-14 | 1999-12-30 | Basf Ag | Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5866755A (en) | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
-
1994
- 1994-06-14 DE DE0705334T patent/DE705334T1/de active Pending
- 1994-06-14 WO PCT/US1994/006734 patent/WO1994029442A2/en not_active Application Discontinuation
- 1994-06-14 AU AU71081/94A patent/AU684524B2/en not_active Ceased
- 1994-06-14 EP EP94920204A patent/EP0705334A1/en not_active Withdrawn
- 1994-06-14 ES ES94920204T patent/ES2140359T1/es active Pending
- 1994-06-14 US US08/260,452 patent/US5650298A/en not_active Expired - Fee Related
- 1994-06-14 CA CA002165162A patent/CA2165162C/en not_active Expired - Fee Related
- 1994-06-14 JP JP7502191A patent/JPH09500526A/ja active Pending
-
1997
- 1997-07-21 US US08/897,719 patent/US5922927A/en not_active Expired - Fee Related
-
2001
- 2001-02-05 US US09/777,317 patent/US6914124B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4850108A (ja) * | 1971-10-26 | 1973-07-14 | ||
JPS4928702A (ja) * | 1972-07-04 | 1974-03-14 | ||
JPS5069407A (ja) * | 1973-04-26 | 1975-06-10 | ||
JPS5848706A (ja) * | 1981-09-18 | 1983-03-22 | Toshiba Corp | ランキンサイクル装置 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003515314A (ja) * | 1999-06-07 | 2003-05-07 | ウォルフガング ハイレン | 新規の、tetリプレッサーに基づく転写調節タンパク質 |
JP2005527227A (ja) * | 2002-05-29 | 2005-09-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 誘導性の真核生物発現システム |
JP2009538122A (ja) * | 2006-04-18 | 2009-11-05 | ジェノスクリーン | 脳の損傷を診断するためのマーカーとしてのオルニチントランスカルバミラーゼ(otc)の使用 |
KR101393204B1 (ko) * | 2006-04-18 | 2014-05-21 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 뇌 손상을 진단하기 위한 마커로서의 오르니틴 트랜스 카바밀라제(otc)의 용도 |
Also Published As
Publication number | Publication date |
---|---|
WO1994029442A3 (en) | 1995-02-02 |
AU684524B2 (en) | 1997-12-18 |
EP0705334A1 (en) | 1996-04-10 |
ES2140359T1 (es) | 2000-03-01 |
DE705334T1 (de) | 1999-12-30 |
US20020086426A1 (en) | 2002-07-04 |
US6914124B2 (en) | 2005-07-05 |
CA2165162A1 (en) | 1994-12-22 |
US5650298A (en) | 1997-07-22 |
WO1994029442A2 (en) | 1994-12-22 |
CA2165162C (en) | 2000-05-23 |
US5922927A (en) | 1999-07-13 |
AU7108194A (en) | 1995-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6914124B2 (en) | Tetracycline-regulated transcriptional activator fusion proteins | |
US5888981A (en) | Methods for regulating gene expression | |
US5859310A (en) | Mice transgenic for a tetracycline-controlled transcriptional activator | |
JP4054058B2 (ja) | テトラサイクリン調節される転写モジュレーター | |
US5464758A (en) | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters | |
US5589362A (en) | Tetracycline regulated transcriptional modulators with altered DNA binding specificities | |
US5654168A (en) | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units | |
US6242667B1 (en) | Transgenic organisms having tetracycline-regulated transcriptional regulatory systems | |
US6271348B1 (en) | Tetracycline-inducible transcriptional inhibitor fusion proteins | |
US5789156A (en) | Tetracycline-regulated transcriptional inhibitors | |
CA2376665C (en) | Novel tet repressor-based transcriptional regulatory proteins | |
US6004941A (en) | Methods for regulating gene expression | |
JP4424761B2 (ja) | 段階的なトランス活性化能を有する転写活性化因子 | |
JPH11507539A (ja) | 真核生物における誘導的遺伝子発現のための自己制御性テトラサイクリン調節系 | |
US20030022315A1 (en) | Tetracycline-inducible transcriptional inhibitor fusion proteins | |
AU4456699A (en) | Tetracycline-regulated transcriptional modulaters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050125 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050112 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050426 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050523 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050524 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050728 |
|
A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20051020 |